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Distal retinal ganglion cell axon transport loss and
activation of p38 MAPK stress pathway following
VEGF-A antagonism
R Foxton*,1, A Osborne2, KR Martin2,3,4,5, Y-S Ng1,6 and DT Shima*,1
There is increasing evidence that VEGF-A antagonists may be detrimental to neuronal health following ocular administration. Here
we investigated firstly the effects of VEGF-A neutralization on retinal neuronal survival in the Ins2Akita diabetic and JR5558
spontaneous choroidal neovascularization (CNV) mice, and then looked at potential mechanisms contributing to cell death. We
detected elevated apoptosis in the ganglion cell layer in both these models following VEGF-A antagonism, indicating that even when
vascular pathologies respond to treatment, neurons are still vulnerable to reduced VEGF-A levels. We observed that retinal ganglion
cells (RGCs) seemed to be the cells most susceptible to VEGF-A antagonism, so we looked at anterograde transport in these cells,
due to their long axons requiring optimal protein and organelle trafficking. Using cholera toxin B-subunit tracer studies, we found a
distal reduction in transport in the superior colliculus following VEGF-A neutralization, which occurred prior to net RGC loss. This
phenomenon of distal transport loss has been described as a feature of early pathological changes in glaucoma, Alzheimer’s and
Parkinson’s disease models. Furthermore, we observed increased phosphorylation of p38 MAPK and downstream Hsp27 stress
pathway signaling in the retinas from these experiments, potentially providing a mechanistic explanation for our findings. These
experiments further highlight the possible risks of using VEGF-A antagonists to treat ocular neovascular disease, and suggest that
VEGF-A may contribute to the maintenance and function of axonal transport in neurons of the retina.
Cell Death and Disease (2016) 7, e2212; doi:10.1038/cddis.2016.110; published online 5 May 2016
Vascular endothelial growth factor (VEGF-A) antagonists were
originally developed to treat cancer, before being used for ocular
application in wet age-related macular degeneration (wet
AMD).1 Their use in the eye has since expanded, and they are
now approved for diabetic macular edema, retinal vein occlu-
sion, plus given off-label for conditions such as neovascular
glaucoma. These drugs’ mechanism of action is to neutralize
pathological increases in VEGF-A, thus removing a potent
angiogenic stimulus and source of vascular hyperpermeability.
VEGF-A was initially named following discovery of its potent
effects on endothelium. However, contrary to its 'vascular'-
specific title, VEGF-A acts on multiple tissues, including in the
nervous system. VEGF-A is neurogenic and neuroprotective
in a variety of different cell types, in vitro and in vivo.2–5 These
findings raised the possibility that blocking VEGF-A when
treating neovascular disease could adversely deprive neurons
of an essential survival factor.
We initially investigated this in models of ischemia–
reperfusion injury,6 then ocular hypertension (OHT), to parallel
a disease scenario where VEGF-A antagonists are used in the
clinic, namely for neovascular glaucoma, or as an adjunct to
trabeculectomy surgery.7 We found in both models that
exogenously injected VEGF-A was protective, but also
VEGF-A-neutralization exacerbated retinal damage. This
indicates tissue sources of VEGF-A are critical to neuronal
survival6,7 and part of the tissue’s response to injury.
Furthermore, using cultured purified primary retinal ganglion
cells (RGCs), we discovered that VEGF-A directly protected
retinal neurons against H2O2-induced caspase-3-mediated
apoptosis via VEGFR-2 signaling and the Pi3-kinase/Akt
axis.7
These data lead us to consider the impact of anti-VEGF-A
therapy in diabetes and wet AMD, the biggest areas of
treatment in terms of patient numbers, and also investigate
possible causes of neuron death. In this report we examined
cell death following anti-VEGF-A treatment in Ins2Akita
diabetic8 and JR5558 spontaneous choroidal neovasculariza-
tion (CNV) mice.9 We established that VEGF-A antagonists
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also accelerate neuronal apoptosis in these models, findings
that may have implications for treating ocular neovascular
disease with anti-VEGF drugs.
We next sought to find potential mechanisms contributing to
neuron loss. We examined the effect of VEGF-A neutrali-
zation on synapses in the inner and outer plexiform layers
(INL and ONL, respectively) and also axon transport along
the visual pathway. RGCs have long axons that project
uninterrupted from the retina to the superior colliculus (SC)
in rodents, and as such require efficient transport to function
well. We used cholera toxin B subunit (CTB) to quantify
anterograde transport in the retina, optic nerve and SC of rats
treated with a VEGF-A neutralizing agent. Furthermore, we
investigated activation of p38 mitogen-activated kinase
(p38 MAPK) and downstream heat-shock protein 27 (Hsp27)
pathways in VEGF-A antagonist treated retinas, which have
been reported to contribute to anterograde transport loss
in glaucoma models.10 Our findings suggest that VEGF-A
antagonists cause a distal reduction of RGC transport
and activation of p38MAPK, whichmaymediate these effects.
We believe that our experiments are important for providing
further insight into the role of VEGF-A in retinal neuronal
homeostasis.
Results
VEGF-A neutralization exacerbates cell death in diabetic
and spontaneous CNV models. Previously we showed
VEGF-A antagonism accelerates neuronal death in a disease
model of glaucoma. Here we extend these findings to
models of diabetic retinopathy, as well as spontaneous CNV,
akin to wet AMD, which unlike the glaucoma model have
VEGF-driven pathology.9,11 We used Ins2Akita diabetic mice,
which have elevated levels of apoptotic nuclei in the ganglion
cell layer (GCL) (Supplementary Figure S1A; Po0.01). After
two weekly intravitreal injections, a significant 2.2-fold
increase in RGC apoptosis from 3.6± 1.5 to 7.9± 1.2 cells/
retina in the GCL above IgG1 control was observed following
soluble VEGFR-2/Fc chimera (sVEGFR-2) treatment
(Figure 1a; Po0.01).
Following this, we examined whether these findings applied
to spontaneous CNV mice. JR5558 have abundant photo-
receptor apoptosis surrounding neovascularization,9 and
higher levels of RGC death compared with wild-type
(Supplementary Figure S1B; Po0.01). Treatment with
sVEGFR-2 by intravitreal injection significantly reduced both
CNV area and number by approximately 50% compared with
IgG1 control (Supplementary Figures S1D and E; Po0.01).
Figure 1 VEGF-A antagonism increases neuronal death in Ins2Akita diabetic and JR5558 spontaneous CNV models. (a) VEGF-A neutralization, via intravitreal injection of
4 pmol sVEGFR-2, significantly elevated RGC death in the Ins2Akita mouse model, above IgG1 and uninjected controls, plus wild-type. N= 7–15. (b) sVEGFR-2 administration in
the JR5558 eye had no significant effect on TUNEL staining in the ONL (left graph), but in the GCL apoptosis was increased 1.8-fold above IgG1 control (right graph). N= 12–14.
*Po0.05, **Po0.01, ***Po0.001. Data are given as means±S.E.M.
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Neuronal death in the JR5558 was unchanged in the outer
nuclear layer (ONL) between-treatment groups (Figure 1b);
however, in the GCL apoptotic nuclei rose significantly 1.8-fold
(Figure 1b; Po0.05) following sVEGFR-2 (8.3±1.1 to
15.0±2.1 cells/retina). Interestingly, increases in cell death
following VEGF-A antagonist treatment were also observed in
wild-type animals serving as controls for both Ins2Akita and
JR5558, which significantly rose from 1.3±0.3 and 2.0± 0.8 in
untreated and IgG treated retinas, respectively, to 8.0± 2.0
cells/retina in the GCL following sVEGFR-2 (Supplementary
Figure S1C; Po0.01). This indicates RGC loss may occur
after VEGF-A blockade independently of the model used.
Retinal synapse architecture is not affected by VEGF-A
neutralization. Our data show that VEGF-A antagonists
also elevate neuronal death in models of diabetes and wet
AMD; however, the cause of neuron loss in these models has
not yet been examined. Is retinal neuron death the
consequence of removing an essential survival factor, or
does VEGF-A influence the normal physiology of these cells?
We investigated two properties of retinal neurons: synaptic
architecture and axon transport, which are critical to the
normal functioning of the cells.
VEGF-A has been reported to regulate synapses through
enhancing synaptic transmission in vitro12 and modulating
synaptic plasticity in development independently of neuro- and
angiogenesis in the adult mouse hippocampus.13 With this in
mind, we investigated if VEGF-A blockade may alter the
synaptic architecture of retinal inner and outer plexiform layers
(IPL and OPL, respectively). These synaptic connections can
be deregulated in ocular diseasemodels,14 sowe used normal
C57Bl/6J mice to avoid this confounding influence. Quantifica-
tion of presynaptic synpatophysin, postsynaptic PSD-95,
then colocalization of the two markers as synaptic 'puncta'
(Supplementary Figure S2A), following intravitreal injection of
sVEGFR-2 or IgG1, was carried out as previously described.
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No significant difference between treatment groups was
observed in either IPL (Supplementary Figure S2B) or OPL
(Supplementary Figure S2C), at central, medial or peripheral
sites of the retina (left, middle and right panels, respectively).
These data indicate that acute VEGF-A antagonism does not
affect gross synaptic architecture in the adult mouse retina.
Anterograde axonal transport is disrupted distally in the
visual pathway. We have consistently observed increased
cell death in RGCs in our studies. These cells have lengthy
axons that project from the retina, primarily to the SC in
rodents, and require optimal axonal transport to function
effectively. Using CTB labeling, we investigated whether
VEGF-A antagonism disrupts anterograde transport in
RGCs. We used normal female Brown-Norway rats to avoid
complicated interactions of pathology on axon transport,
which are compromised in many disease models.16,17 We
injected rat eyes intravitreally with either IgG1 or sVEGFR-2,
then 7 days later administered CTB via the same route and
harvested the tissue at 4, 8, 24 and 48 h post-CTB.
First we quantified accumulation of CTB in RGC axon
termini in the SC (Figure 2a), shown as overall fluorescence
intensity (mean gray level) and maximum fluorescence (peak
intensity) in the graphs. At 4 and 8 h after injection, CTB was
not present in the SC (data not shown), presumably as it had
not yet travelled the full length of RGCs. At 24 h post-injection
clear CTB labeling was present (Figure 2b, left panels), and
although therewas a trend toward a decrease in peak intensity
of CTB staining following sVEGFR-2 (Figure 2b, bottom right
panel; P= 0.09), there was no statistically significant differ-
ence between the groups in the overall mean gray fluores-
cence level (Figure 2b, top right panel). At 48 h after CTB, build
up of the tracer had increased further (Figure 2c, right panels);
however, this time there was a significant reduction in CTB
accumulation in sVEGFR-2 treated eyes. Both mean gray
level and peak intensity (Figure 2c, left panels) were reduced
in comparison with IgG1, indicating anti-VEGF-A treatment
may attenuate distal axon transport in RGCs. The temporal
profile of CTB accumulation in IgG1 and sVEGFR-2 treated
retinas indicates that fast axonal transport may be affected,18
as differences were observed at just 48 h post-CTB injection.
Distal anterograde transport deficit is not caused by
reduced uptake of CTB into RGCs. A number of neurode-
generative disease models are characterized by axon
transport deficits, often manifesting as early signs of
pathology. These frequently first appear in the distal portion
of neurons, then progress to more proximal regions.16,19,20
We looked at the dynamics of CTB transport elsewhere in the
visual pathway to see if the transport loss was observed in
more proximal regions; firstly in the retina, then optic nerve.
CTB is taken into RGCs via GM1 ganglioside receptor
binding,21 and we firstly quantified tracer fluorescence in the
retina as a readout of uptake. We generated images of the
whole retina using confocal microscopy, to quantify CTB in
eyes from these studies, at 4, 8, 24 and 48 h post-injection
(Figure 3a). Fluorescence intensity appeared to increase
over time, up to 24 h after delivery of tracer, then decline at
48 h. We found no significant difference in CTB uptake
between treatment groups at any of the time points
(Figure 3b). High-magnification images of retinas at 48 h
post-injection showed a similar distribution of CTB in RGCs of
IgG1 versus sVEGFR-2 treated eyes (Figure 3c). These data
indicate that uptake of CTB into the retina is not affected by
VEGF-A antagonism.
Levels of CTB in the optic nerve are unaffected by
VEGF-A neutralization. CTB staining in the optic nerve also
did not appear to be affected by sVEGFR-2 IVT injection.
Area under the curve analysis of fluorescence intensity from
longitudinal optic nerve sections (Figures 4a and b) showed
that CTB uptake increased over time post-CTB injection in
the optic nerve, from 4 to 48 h. Pre-treatment with the
VEGF-A antagonist had no significant impact on this
accumulation, either at 4, 8, 24 or 48 h (Figure 4c).
Taken together, the data from SC, retina and optic nerve
indicate that anti-VEGF-A induces a distal loss of CTB labeling
along RGC projections, which after a single acute dose of
sVEGFR-2 does not manifest in proximal transport disruption.
Axonal transport changes precede cell loss. Next, we
wanted to determine whether changes in axon transport were
early signs of injury, or if they accompanied significant
neuron loss in the GCL. Tissue was stained with DAPI
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(4',6-diamidino-2-phenylindole), and high-resolution images
were generated to quantify RGCs in central, medial or
peripheral locations in whole-mounted retinas (Figure 5a).
Isolectin-B4 counterstaining excluded retinal vessels from
cell counts. We observed no significant difference in neuron
number at any of the separate regions of the retina
(Figure 5b), suggesting that changes in anterograde trans-
port occur early, prior to soma loss.
Increased phosphorylation of p38 MAPK and Hsp27, but
not Tau, accompany transport deficits. Finally, we looked
for evidence of activation of signaling pathways that might
contribute to distal anterograde transport loss following
VEGF-A neutralization. P38 mitogen-activated protein
kinases (p38 MAPK) are a class of MAPK responsive to
stress signaling, and phosphorylation of these has a strong
association with neurodegenerative disease.22,23 In the
retina, elevated phosphorylated p38 MAPK (p-p38 MAPK)
and downstream targets, Hsp27 and Tau, are associated with
RGC injury and loss of anterograde transport in rodent
models of OHT.10,24 With this in mind, we did immunostaining
to localize phosphorylated p38 MAPK, Hsp27 and Tau on
retinas from anterograde transport experiments.
We observed low background perinuclear p-p38 MAPK
immunofluorescence in the retina after IgG1 administration
(Figure 6a, left panels); however, in sVEGFR-2 treated tissue
this was substantially increased, both in terms of level and
number of cells expressing p-p38 MAPK (Figure 6a, right
panels), with some cells exhibiting strong nuclear localization
(arrows). Further examination of this staining revealed these
cells to be mostly GFAP-positive, indicating astrocyte expres-
sion (Supplementary Figure S3A). However, a lesser number
of cells were co-labeled with CTB, signifying RGCs also
upregulated p-p38 MAPK (Supplementary Figure S3B).
Immunostaining for phosphorylated Hsp27 also revealed
activation of this downstream target. In IgG1 treated eyes
(Figure 6b, left panels), low level of Hsp27 phosphorylation
was observed, but after sVEGFR-2 treatment intense staining
was observed in cells sitting on top of RGCs (Figure 6b, right
panels). GFAP colocalization revealed these cells to be
astrocytes. In contrast, we were unable to see any change in
hyperphosphorylated Tau protein, another target of p38
MAPK, perhaps indicating a more specific downstream
activation of Hsp27. In the optic nerve and SC (data not
shown) we found no differences in p-p38 MAPK, p-Hsp27 or
p-Tau levels in between-treatment groups. These data show
that p38 MAPK signaling pathways are activated in the retina
in response to VEGF-A antagonism.
Discussion
We provide here additional evidence that VEGF-A is a critical
survival factor for neurons, and that neutralization can
exacerbate cell death. Previous work by ourselves and others
demonstrated this in the neural retina following VEGF-A
depletion via local or systemic injection of neutralizing
agents,6,7,25 which did not affect normal adult vasculature
but enhanced neuronal apoptosis in the inner and outer retina.
We show here in Ins2Akita type I diabetic and JR5558
spontaneous CNVmouse models that even when the disease
phenotype responds to anti-VEGF-A treatment (as the
neovascular lesions in the CNV mouse did) neuronal cell
death is exacerbated not diminished.
VEGF-A levels are increased in the eye in both the diabetic
and CNV models,9,11 in line with patient data for both diabetic
retinopathy26 and wet AMD.1 Pathologically elevated VEGF-A
levels are a key feature of ocular neovascular disease, driving
angiogenesis and vessel leakage. However, one possibility
may be that in early stages VEGF-A is produced to protect
neurons from degeneration. In a rat model of IOP elevation,
diabetes was observed to be neuroprotective against acute
RGC loss.27 Additionally epidemiological studies have
proposed that the early stages of diabetes may be neuropro-
tective against glaucoma.28,29 It is not yet clear if VEGF-A
is linked to this protection; however, our evidence in disease
models suggests that removing tissue sources of this
molecule may be deleterious.
Does the increase in retinal neuron apoptosis with anti-
VEGF-A simply reflect loss of a survival factor? The retina has
a high metabolic demand,30 so that even under normal
conditions cells may be greatly exposed to reactive oxygen
and nitrogen species. Loss of VEGF-A, and downstream
Pi3-kinase/Akt signaling, may leave cells vulnerable to insult.
However, we also explored whether VEGF-A could have a
more integral role in the normal physiology of the cells, by
looking at two aspects of retinal neuron function: synapse
architecture and anterograde axon transport. VEGF-A is
reported to influence synaptic connectivity,12,13 but after
delivery of VEGF-A antagonist to control mice retinas we
found no alteration in synaptic puncta number in IPL or OPL.
This may be because VEGF-A is more critical in development,
and perhaps is not essential for regulation of adult tissue.
Although synapse number did not alter, data from our
anterograde transport studies indicate that RGCs lose some
ability to transport molecules along the visual pathway
following VEGF-A neutralization, an effect preceding reduc-
tion in neuron numbers.We observed a significant decrease in
CTB-labeling in the SC, the distal projection site of RGCs,
Figure 2 VEGF-A neutralization reduces cholera toxin B (CTB) labeling in the superior colliculus. Brown-Norway rats were injected bilaterally IVTwith 20 pmol of either IgG1
or sVEGFR-2, and 7 days later received IVT 2 μl of 0.75% CTB. Brains were harvested and frozen coronal sections of the SC prepared. (a) Quantification methodology. Frozen
sections were stained with Nissl (magenta) and DAPI (blue) (left panel) to allow unbiased selection of SC regions (right panel), even when CTB signal (green) was weak. Left and
right SC of each brain slice were analyzed independently. (b) At 24 h post-CTB injection, no significant differences between treatment groups were observed in the mean gray
level (8.8± 1.7 versus 6.4± 2.4; IgG1 versus sVEGFR-2, respectively; top graph), or peak fluorescence intensity (76.8± 22.0 versus 32.7± 9.1; IgG1 versus sVEGFR-2,
respectively; bottom graph)(both arbitrary units). Left panels show representative images of CTB labeling with these treatments. (c) At 48 h post-CTB significant reductions were
seen in both mean gray level (31.4± 2.2 versus 23.3± 2.2; IgG1 versus sVEGFR-2, respectively; top graph) and peak intensity (50.4± 2.8 versus 35.2± 5.1; IgG1 versus
sVEGFR-2, respectively; bottom graph) in the sVEGFR-2 treatment group compared with IgG1. Right panels; representative images of CTB labeling 48 h post-injection of IgG1
(top panel) or sVEGFR-2 (bottom panel) treatment groups. *Po0.05, N= 6. Data are given as means± S.E.M. Original magnification= × 4
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48 h after CTB injection. In contrast, CTB uptake into the retina
and along the proximal portion of the optic nerve prior to the
optic chiasm did not diminish. Distal transport loss has been
well described as an early sign of neuropathy in many disease
models, involving progressive distal to proximal loss of
function along axonal projections, followed by eventual
degeneration of the soma. In the DBA/2J model of glaucoma,
anterograde transport impairment is first observed in the SC,
followed by the optic nerve and eventually the retina as the
animals age and pathology worsens.16 Distal injury is also one
of the earliest hallmarks of neuronal degeneration in models of
Alzheimer’s and Parkinson’s disease, as well as amyotrophic
lateral sclerosis.19,20,31
In this study, like others investigating anterograde transport
along RGCs,10,16 the site of transport reduction and axonal
injury was not pinpointed. We did however observe alterations
in retinal signaling following VEGF-A antagonist delivery that
may provide some mechanistic understanding. Activation,
through phosphorylation, of p38 MAPK, and downstream
Hsp27 are associated with stress signaling, and contribute to
axon transport deficits and pathology of both mouse and
rat models of glaucoma.32,33 Conversely, inhibition of p38
activation can prevent these transport losses.10 Following
VEGF-A neutralization, we found strong expression of both
phosphorylated p38 MAPK and Hsp27 throughout the inner
retina. Expression was not limited to RGCs however, but found
largely in astrocytes, so we are unable to specify how much of
the axon transport deficits are the direct result p38 MAPK and
Hsp27 activation in RGCs, or via paracrine signaling through
glial cells. Interestingly, we also saw no evidence of Tau
hyperphosphorylation, another downstream target of p38,
which has a strong association with neurodegenerative
processes and disease.34,35
The contribution of these signaling pathways, and a more
precise role of VEGF-A in axon transport, should be further
evaluated. Currently there are a lack of well-established in vitro
or ex vivo assays to allow monitoring of gross movement of
molecules anterogradely in neurons, making it difficult to fully
Figure 3 Anti-VEGF-A treatment does not affect CTB uptake into the retina. (a) Rat eyes were bilaterally injected IVTwith 20 pmol IgG1 or sVEGFR-2, then 7 days later with
2 μl of 0.75% CTB. The tissue was dissected, flat mounted and confocal tile scans made of entire retinas harvested at 4 (left panels), 8 (middle left panels), 24 (middle right
panels) and 48 h (right panels) post-CTB injection. Original magnification= × 4. (b) Quantification of mean gray levels indicated an increase in fluorescence intensity of CTB in the
retina from 4 to 24 h post-injection; however comparison of IgG1 and sVEGFR-2 groups revealed no significant differences between treatments at any of the time points.
(c) Higher magnification images of RGCs showed no variation in intracellular accumulation of CTB using × 10 (upper panels) or × 40 (lower panels) magnification at 48 h post-
CTB injection, with IgG1 (left panels) or sVEGFR-2 (right panels) treatment. White boxes on upper panels indicate regions that were imaged using × 40 objective for the lower
panels. N= 6–10. Data are given as means± S.E.M.
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assess the contribution of VEGF-A. However, understanding
these pathways may be significant, because even transient
losses of anterograde transport or survival signaling
could leave neurons vulnerable. Currently we are not aware
of other studies investigating the role of VEGF-A in axon
transport; however, there may be indirect evidence. An
Figure 4 CTB transport in the proximal portion of the optic nerve is not affected by VEGF-A neutralization. (a) Tile scan confocal images of longitudinal sections of the entire
optic nerve, between the posterior globe and optic chiasm, were used to quantify CTB anterograde transport along the optic nerve (top panel). Measurements of fluorescence
intensity were taken at 100 μm intervals (bottom panel; white vertical lines representing 100 μm), plotted over the length of the tissue (b); data from 48 h post-CTB injection time
point, and used to calculate the area under the curve (c). AUC fluorescence intensity increases with time post-CTB injection; however, no significant differences were observed at
any of the time points between IgG1 and sVEGFR-2-treatment groups. For presentation purposes, only data points every 500 μm are shown in (b); however, AUC was calculated
from 100 μm intervals along the optic nerve. N= 3–10 optic nerves. Data are given as means± S.E.M. Original magnification= × 4
Figure 5 Reductions in CTB transport precede cell body loss. (a) Retinas from 48- h post-CTB injection transport experiments were stained with DAPI (blue) and IB4
(magenta) (left panel). Tile scan images of each of the four petals were taken (original magnification= × 10), 0.5mm2 areas were selected at 0.5, 2.0 and 3.5mm from the optic
nerve (middle panel), and then processed to remove the vascular area from each picture (right panel). DAPI-stained nuclei were counted using ImageJ software. (b) A comparison
of DAPI nuclei per mm2 revealed no significant differences between IgG1 or sVEGFR-2 treatments at 0.5, 2.0 or 3.5mm from the optic nerve. These data indicate that at 1-week
post-sVEGFR-2 injection, transport deficits may precede significant RGC loss. N= 5–6 retinas. Data are given as means± S.E.M.
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increase in sensory neuropathies has been reported in
cancer patients receiving VEGF-A antagonists in combination
with chemotherapy,36,37 which is not attributed solely to
chemotherapeutics.38 Nociceptors, like RGCs have long
axons, and require efficient movement of proteins and
organelles to function. It is possible VEGF antagonists
interrupt transport along these sensory neurons, contributing
to painful neuropathies.
Is there reason to be concerned about neuronal side effects
of VEGF antagonists in ocular neovascular disease in
humans? Typically clinical trials for diabetic macular edema
and wet AMD do not include assessment of neuronal survival
or function, so it is difficult to directly compare our results with
clinical data. However, some studies have emerged looking at
aspects of retinal health following anti-VEGF-A treatment.
Notably, the Comparison of Age-Related Macular Degenera-
tion Treatments Trials (CATT) monitored 1024 patients for
signs of geographic atrophy (GA), who did not display this
upon enrollment. After 2 years of bevicizumab or ranibizumab
treatment, 18.3% of patients developed GA, leading the
authors to conclude that anti-VEGF-A treatment may have a
role in the development of GA.39 Additionally, the SEVEN-UP
study, assessing 7–8 year outcomes in 65 AMD patients
receiving ranibizumab treatment, found a mean decline in
letter score of 8.6 letters, and in 37% of patients, visual acuity
of 20/200 or worse.40 As yet, there are no similar studies for
diabetic macula edema; however, given that diabetic patients
begin treatment at a younger age, and therefore receive
therapy more chronically, longitudinal studies could be
initiated to monitor the health of these patient’s eyes.
Currently VEGF-A antagonists still represent the best
pharmacological treatment for wet AMD, diabetic macular
edema and retinal vein occlusion, with the benefits very clearly
outweighing the risks, at least in the short term. However,
Figure 6 Changes in axon transport are accompanied by increased expression of phosphorylated p38 MAPK and downstream Hsp27, but not Tau. (a) Immunolocalization of
phosphorylated p38 MAPK (p-p38 MAPK; magenta), in retinas from the 48-h post-CTB injection transport studies, revealed increased expression in eyes treated with sVEGFR-2
(right panels), in comparison with IgG1 controls (left panels). Original magnification= × 10; green=CTB, blue=DAPI. Higher magnification (×40) images (left middle and right)
showing elevated p-p38 MAPK as well as nuclear localization in some cells (arrows) in sVEGFR-2 treated retinas. (b) Differences in expression of phosphorylated Hsp27 were
also observed between IgG1 (left panels) and sVEGFR-2 (left panels) treatment. Phosphorylated Hsp27 (green) was strongly upregulated following sVEGFR-2 administration,
and colocalized with GFAP (red),41 indicating astrocyte expression. Blue=DAPI. Left and right middle panels – original magnification= × 10; left middle and right
panels – original magnification= × 40. (c) In contrast, no changes were detected in phosphorylated Tau levels between IgG1 (left panels) and sVEGFR-2 (right panels).
Red= p-Tau, green=CTB, blue=DAPI. Original magnifications= × 10 (left and right middle) and × 40 (left middle and right)
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future drug discovery efforts for ocular neovascular disease
should include extensive preclinical assessment of neuronal
function and/or potential damage before entering into humans.
Perhaps neuroprotective agents should be considered more
widely for clinical use, in combination with agents that act on
vascular targets, because irrespective of disease etiology, the
long-term goal for treating ocular neovascular disease is to
prevent neuronal loss.
Materials and Methods
Animals. Animals were obtained from Harlan Laboratories (Shardlow, UK),
Charles River (Margate, UK) or in-house colonies and used according to UK Home
Office (http://goo.gl/YLUFmF, last accessed 26th October 2015) and the Association
for Research in Vision and Ophthalmology Statement for the Use of Animals in
Ophthalmic and Vision Research guidelines (http://goo.gl/OwwfLZ, last accessed
26th October 2015). All animals received food and water ad libitum, in a 12-h
day/night cycle, temperature-controlled environment.
When required, mice were anesthetized by intraperitoneal (IP) injection of xylazine
(0.5 mg/kg) and ketamine (100 mg/kg) in water. Rats were anesthetized by IP
injection of 37.5 mg/kg ketamine and 0.25 mg/kg medetomidine hydrochloride. Pupils
were dilated with phenylephrine hydrochloride 2.5% and tropicamide 1% (Bausch and
Lomb, Surrey, UK) before intravitreal injections.
Ins2Akita. Ins2Akita mice were obtained from Jackson Lab (Bar Harbor, ME, USA,
stock number 003548). The Ins2Akita mouse has a mutation in the insulin 2 gene,
and develops hyperglycemia from approximately 3–4 weeks old.8 Experimental
mice were generated by mating Ins2Akita heterozygous males with C57BL/6
J females, and diabetes was confirmed by blood glucose measurements exceeding
250 mg/dl. Six-week-old heterozygous males of C57BL/6J background and age-
matched non-diabetic siblings were used in the study. Mice were anesthetized and
administered with 4 pmol in 1 μl of either soluble VEGFR-2 (sVEGFR-2;
357-KD-050/CF; R&D systems, Abingdon, UK) or IgG1 control (110-HG-100;
R&D Systems), via a bilateral intravitreal injection. Seven days later the intravitreal
injections were repeated, and after a further 7 days the animals were killed by CO2
asphyxiation, the eyes removed and fixed in 4% paraformaldehyde (PFA) for TUNEL
staining as described below. Animals used in this study were killed at 8 weeks old,
and at death Ins2Akita mice displayed significant hyperglycemia and reduced weight
in comparison with C57Bl/6J controls (Table 1), in line with previous reports.8
JR5558. JR5558 mice were discovered at The Jackson Laboratory, and bred and
maintained from in-house colony as previously described.9 Both male and female
age-matched littermates were used for experiments. Mice were anesthetized and
administered with either 4pmol in 1 μl of sVEGFR-2 or IgG1 control, via a bilateral
intravitreal injection. After 7 days the animals were killed by CO2 asphyxiation, and
the eyes enucleated and fixed in 4% PFA for TUNEL staining. Fluorescein
angiography was carried out the day prior to intravitreal injection as well as tissue
harvest, as detailed below.
Fluorescein angiography. Fundus photography and retinal angiography
were performed on conscious mice as previously described.9 Lesion number and
area were quantified using ImageJ (http://imagej.nih.gov/ij/; provided in the public
domain by the National Institutes of Health, Bethesda, MD, USA). Lesion area is
represented in figures as the percentage of control; however, statistics were done
on raw pixel measurements. Investigator (RF) was blinded to treatment groups.
TUNEL staining. TUNEL staining was carried out on whole mount tissue.
Retinas were dissected out and permeabilized in 3% Triton X-100 in PBS (T-PBS)
for 2 h at room temperature (RT). The TUNEL protocol was performed according to
the manufacturer’s instructions (Promega, Southampton, UK), and the retinas were
then stained with 1:500 biotinylated isolectin-B4 (IB4; Sigma-Aldrich, Dorset, UK)
overnight at 4 °C, followed by 1:500 streptavidin labeled with AlexaFluor 594 for 2 h
at RT. Tissue was washed in 0.3% T-PBS with 5 mM DAPI and flat mounted in
Vectashield (Vector Laboratories, Peterborough, UK). To quantify TUNEL-positive
neurons, we used a Zeiss 710 confocal microscope (Zeiss, Oberkochen, Germany),
taking tile scans of the entire retina, with 30 μm Z-stacks through the GCL and/or
ONL using a × 10 magnification water-immersion objective. IB4 staining and
morphological criteria discriminated non-neuronal (endothelial and glial) cells from
neuronal cells. The total number of TUNEL positive cells in the GCL or ONL were
counted, and investigator (RF) was blinded to treatment groups.
Transport assay. Female Brown-Norway ex-breeder rats were used for all
in vivo transportexperiments, due to ease and accuracy of intravitreal injection for
quantification of axon transport. Rats were anesthetized and administered with
either 20 pmol in 3 μl of sVEGFR-2, or IgG1 control, via a bilateral intravitreal
injection. After 7 days animals were injected with 2 μl of a 0.75% solution of
AlexaFluor 488-conjugated cholera toxin B subunit (CTB; Life Technologies, Paisley,
UK) in sterile PBS. Following injection the needle was held in place for 1 min to
prevent reflux of tracer. Rats were deeply anesthetized with pentobarbital sodium,
before being transcardially perfuse-fixed with 75 ml of PBS, followed by 75 ml of 4%
PFA, at 4, 8, 24 and 48 h post-CTB injection. Eyes, optic nerves and brains were
removed for histology.
Brain preparations. Brains were dehydrated (30% sucrose+0.1% sodium
azide) and the SC sectioned (30 μM) using a freezing microtome (SM2400; Leica
Inc., Wetzlar, Germany). Orientation was confirmed through a needle mark to the
right midbrain, visible on all sections.
Sections were blocked (0.3% triton, 5% normal goat serum (NGS) in PBS),
counter-labeled with Nissl (1:200; Life Technologies) and DAPI (1:10 000; Life
Technologies) and imaged using epifluorescent microscopy (DM6000 microscope;
Leica Inc.). Images were taken using a 5 × air objective and merged together using
Adobe Photoshop CS5 (Adobe Systems, San Jose, CA, USA) to represent the
entire SC.
Approximately 10 sections per brain were chosen for analysis based on consistent
central SC morphology and cerebral aqueduct shape and size. Quantitative analysis
of CTB fluorescence intensity was measured using ImageJ software (http://imagej.
nih.gov/ij/; provided in the public domain by the National Institutes of Health,
Bethesda, MD, USA), and fluorescence measured in arbitrary units (0= black,
255=white).
Mean gray level fluorescence intensity was calculated by outlining the right and left
superior colliculi with the same 'D'-shaped polygon (matching the shape of each
colliculus). Intensity profiles for each treatment were created by measuring
fluorescence from the outer edge of the SC towards the central midbrain at three
evenly spaced regions. Mean data were plotted as a line graph of fluorescent intensity
against distance and the area under the curve (AUC) calculated. AUC provided a
measurement for cumulative fluorescence across the SC. Peak fluorescent intensity
within these regions was also determined. Investigator (AO) was blinded to treatment
groups.
Optic nerve preparations. Optic nerves were dissected between the
posterior globe and the optic chiasm, and post-fixed overnight in 4% PFA at 4 °C.
The tissue was then washed three times in PBS, mounted in optimum cutting
temperature compound (OCT) (TissueTek; Sakura Finetek, Thatcham, UK) and
10 μm longitudinal frozen sections were prepared. The sections were mounted on
microscope slides in Vectashield with DAPI. Tile scan images of the whole optic
nerves were taken using a Zeiss 710 confocal microscope, with identical gain
settings for each individual section. Mean fluorescence intensity was measured
across the width of the optic nerve at 100 μm intervals, using ImageJ software,
plotted as a line graph against distance (along the nerve) and the AUC calculated
using Prism software (GraphPad, La Jolla, CA, USA). Investigator (RF) was blinded
to treatment groups.
CTB uptake into the retina. Eyes were post-fixed overnight in 4% PFA
following perfuse-fixation, at 4, 8, 24 and 48 h after intravitreal CTB injection.
Retinas were dissected from the eyecups, and washed three times in PBS, before
being whole mounted on glass slides in Vectashield with DAPI, with the GCL facing
upwards. Tile scan images of the whole retinas were taken using a Zeiss 710
confocal microscope using a × 4 air objective, with identical gain settings for all
Table 1 Weights and blood glucose of 8-week-old C57Bl/6 J and Ins2Akita mice
at the time of death
Mouse strain N Weight (g) Blood glucose (mg/dl)
Wild type 10 24.7±2.3 218.3± 30.4
Ins2Akita 9 21.5±1.6 509.0± 77.8
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tissue. Mean fluorescence intensity was measured across the retina using Adobe
Photoshop, for all time points. Higher magnification images were captured using
× 10 and × 40 water immersion objectives. Investigator (RF) was blinded to
treatment groups.
Quantification of retinal ganglion nuclei. Retinas of Brown-Norway rats
from the anterograde transport experiments were permeabilized in 3% T-PBS for 2 h
at RT, then incubated overnight with 1:500 biotinylated-IB4 at 4 °C, followed by
1:500 streptavidin labeled with AlexaFluor 594 for 2 h at RT. Tissue was washed in
0.3% T-PBS with 5 mM DAPI and flat mounted in Vectashield. To quantify RGCs, we
used a Zeiss 710 confocal microscope (Zeiss, Oberkochen, Germany) with a × 10
water-immersion objective, to take 15 μm Z-stacks through the GCL of each of the
four retina petals. Maximum intensity projections were made of the images, and
then processed using Adobe Photoshop to remove the vascular area from each
picture. An area of approximately 0.5 mm2 at central, medial and peripheral regions
of each petal (0.5, 2.0 and 3.5 mm from the optic nerve, respectively) was selected,
and cells in these regions counted using ImageJ software (NIH), giving 12 images
per whole mount and sampling approximately 3000 cells/retina. RGC counts were
normalized to cells/mm2 before statistics were conducted. Investigator (RF) was
blinded to treatment groups. Investigator (RF) was blinded to treatment groups.
Phosphorylated p38 MAPK, Hsp27 and Tau immunostaining.
Retinas of Brown-Norway rats from the CTB anterograde transport experiments
were permeabilized in 3% T-PBS for 1 h, then blocked for 2 h in 5% NGS in 0.3%
T-PBS at RT, before being incubated with antibodies for phosphorylated p38 MAPK
(1:100; 9216 S; Cell Signaling Technology, Beverly, MA, USA), phosphorylated
Hsp27 (1:100; 9709 S; Cell Signaling Technology), phosphorylated Tau (1:100;
MN1020B; Life Technologies) or GFAP (1:200; Z0334; Dako, Cambridge, UK)
overnight at 4 °C. Retinas were washed in 0.3% T-PBS, before being incubated with
combinations of goat anti-mouse AlexaFluor 555, goat anti-rabbit AlexaFluor 555,
goat anti-rabbit AlexaFluor 594 conjugated secondary antibodies (Life Technologies)
or AlexaFluor 555-conjugated streptavidin (Life Technologies) for 2 h at RT. Tissue
was washed in 0.3% T-PBS with 5 mM DAPI and flat mounted in Vectashield.
A Zeiss 710 confocal microscope, with water-immersion × 10 and × 40 magnification
objectives, was used to take 20 μm Z-stacks through the GCL of IgG1 and
sVEGFR-2 treated retinas, and maximum intensity projections of the cells were
generated. Controls were no primary antibody and relevant IgG isotype controls.
Investigator (RF) was blinded to treatment groups.
Synapse protocol. Quantification of synapse number in the outer (OPL) and
inner plexiform layers was quantified using immunohistochemistry, based on the
method of Ippolito and Eroglu (2010)15 Briefly, 7-week-old C57Bl/6J mice (Charles
River) were anesthetized and administered with either 4pmol in 1 μl of sVEGFR-2
or IgG1 control, via a bilateral intravitreal injection. After 7 days the animals were
deeply anesthetized with pentobarbital sodium, before being transcardially perfused
with 10 ml of PBS. The eyes were enucleated and fixed in 4% PFA for 1 h. The lens
was removed, and eyes were cryoprotected in 30% sucrose, embedded in OCTand
sagittal cryostat sections (10 μm) thaw-mounted onto glass slides. Sections were
blocked in 20% NGS for 1 h at room temperature (RT), before rabbit anti-PSD-95
(1:200; Life Technologies) and mouse anti-synaptophysin (1:500; Abcam,
Cambridge, UK) antibodies in 0.3% Triton X-100 in PBS (T-PBS) with 10% NGS
were added overnight. Slides were then washed 3 x 10 min in PBS, before goat
anti-mouse conjugated to AlexaFluor 488, and goat anti-rabbit conjugated to
AlexaFluor 594 secondary antibodies in 0.3% Triton X-100 in PBS (T-PBS) with 10%
NGS, were added for 2 h at room temperature. Slides were washed a further
4 × 10 min, before mounting in Vectashield with DAPI.
For quantification of synapse number, 5 μm confocal scans were performed
(optical section width, 0.38 μm; 15 optical sections each), at the periphery, middle and
optic nerve portions of each section, on 3 sections per eye (total 9 images). Maximum
intensity projections for each image were generated, and synapse colocalization
quantified as detailed previously.15 Investigator (RF) was blinded to treatment groups.
Statistics. Statistical analyses were performed using GraphPad Prism software
version 6 (GraphPad Software). For comparisons of two treatment groups,
a Student’s t-test was used. For analyzing three or more means, one-way analysis
of variance (ANOVA) with a Newman–Keul’s post hoc test was carried out. For
multiple treatment groups over separate time points, a two-way ANOVA with a
Newman–Keul’s post hoc test was used. Results are means± S.E.M. unless stated,
with each N representing an individual retina; N was at least three for each
statistical analysis. Po0.05 was considered significant.
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